ORAMED PHARMACEUTICALS INC. — Key Metrics
5 years of history · ending 2025-12-31 · SEC EDGAR
Forensics
Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.
F-Score (Piotroski 0-9)
Per Share Metrics
Turnover & Efficiency Analysis (days)
Expense Ratios
Working Capital Analysis
Valuation Multiples
Enterprise Value Multiples
52-Week Range
Trailing Returns
ROIC vs WACC
Yields
Capital Deployment Yields
Liquidity & Leverage Ratios
Earnings Quality (OCF/NI · FCF/NI · Sloan Accruals)
EPS (Diluted)
$2
Book Value Per Share
$5
Free Cash Flow Per Share
$-0
Cash Per Share
$1
Revenue Per Share
$0
OCF Per Share
$-0
Return on Equity↑+67.8pts
37.0%
Return on Assets↑+59.8pts
33.2%
Return on Invested Capital↑+14.5pts
-7.4%
Debt to Equity
0.00
Current Ratio↓-51.1% -$7
6.98
Quick Ratio↓-51.1% -$7
6.98
Asset Turnover↓-66.9% -$0
0.01
Days Payables Outstanding
81.38
R&D / Revenue↓-457.5pts
319.1%
SBC / Revenue↑+199.9pts
299.6%
Capex / Revenue↓-13.4pts
0.4%
Working Capital↑+28.8% +$26M
$114M
Net Current Asset Value↑+39.8% +$38M
$133M
Invested Capital↑+54.8% +$71M
$200M
OCF / Net Income↓-115.5% -$1
-0.14
FCF / Net Income↓-115.2% -$1
-0.14
Accruals Ratio (Sloan)↑+33.1pts
31.7%
Net Debt↑+27.2% +$19M
$-51M
Net Debt / EBITDA↑+17.5% +$1
3.43
Interest Coverage
-14.98
Cash Coverage
-9.86
Capex Coverage↓-1699.0% -$960
-1016.11
Tangible Common Equity↑+71.4% +$83M
$200M
TCE / Total Assets↓-4.5pts
86.5%
NOPAT↑+33.0% +$6M
$-13M
Cash ROIC↑+19.4pts
-5.3%
WC / Revenue↑+2429.3pts
5709.3%
Capex / D&A↓-98.5% -$5
0.07
Reinvestment Rate↑+2.0pts
0.7%
Total Payout Ratio
7.4%
Asset Growth vs Revenue Growth
86.9%
Revenue 5Y CAGR↓-39.2pts
-5.9%
Book Value 5Y CAGR↑+8.7pts
43.5%
Stock Price (FY-end)↓-85.5% -$16
$3
Market Cap
$113M
P/E Ratio
1.76
P/S Ratio
56.35
P/B Ratio
0.56
P/TB Ratio
0.56
Enterprise Value
$61M
EV / Sales
30.67
FCF Yield
-8.1%
Shareholder Yield
-1.1%
Buyback Yield
4.2%
R&D Yield
5.7%
Capex Yield
0.0%
Graham Number
$13
Shares Variation (YoY)
3.8%
Beta (5Y)↑+104.9% +$1
1.23
Cost of Equity↑+3.2pts
10.7%
Cost of Debt (after tax)
3.2%
WACC
6.9%
ROIC - WACC Spread
-14.8%
52W High↓-85.2% -$17
$3
52W Low↓-19.4% -$0
$2
Trailing Return 1Y↓-443.6pts
20.3%
Trailing Return 5Y↓-206.7pts
-38.2%
F-Score (Piotroski)↓-33.3% -$1
2.00
Earnings Forecasts
Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).
Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.